Question 1

What are the potential benefits of axitinib compared to sorafenib for my situation?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer clinical trial (NCT00678392). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from axitinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer clinical trial (NCT00678392). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer clinical trial (NCT00678392). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or my cancer progresses?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer clinical trial (NCT00678392). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there other treatment options available besides this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer clinical trial (NCT00678392). Contact the study team or your healthcare provider for specific answers.

Question 6

How often will I need to come in for treatment and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer clinical trial (NCT00678392). Contact the study team or your healthcare provider for specific answers.

What this study is about